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Cyclosporine suppresses rat hepatic cytochrome P450 in a time-depen-
dent manner.
Background. Cyclosporine is a potent immunosuppressant known to
selectively suppress specific cytochrome P450 (P450) isoforms following
chronic therapy in the rat. Cyclosporine undergoes significant hepatic
metabolism in the rat, primarily due to P450 3A isoforms. Hence,
alterations in hepatic metabolism of cyclosporine may lead to changes in
drug pharmacokinetics or pharmacodynamics. The purpose of this study
was to examine the temporal effect of chronic cyclosporine dosing on P450
protein expression and metabolic activity in a rat model of chronic
cyclosporine nephropathy.
Methods. Adult male rats were administered cyclosporine 15 mg/kg/day
or vehicle 1 ml/kg/day by subcutaneous injection for up to 28 days. To
examine whether or not metabolic activity recovered following drug
removal, additional rats were administered cyclosporine for 28 days
followed by vehicle for up to an additional 15 days. Hepatic P450 protein
expression and microsomal metabolic activity were measured by Western
blot analysis and in vitro steroid hydroxylation, respectively.
Results. Cyclosporine trough levels progressively increased over the 28
days period and were still measurable for up to 15 days after discontinu-
ation. Immunoblot analysis indicated that chronic cyclosporine treatment
suppressed P450 3A2 expression and in vitro steroid hydroxylation in a
time-dependent manner. Fifteen days following discontinuation of cyclo-
sporine dosing, hepatic metabolic activity and microsomal P450 3A2 levels
returned to near pre-dosing levels.
Conclusions. We conclude that the time-dependent P450 suppression by
cyclosporine may at least partially explain the variability in cyclosporine
pharmacokinetics. These studies support the hypothesis that hepatic
isoforms other than P450 3A2 may be responsible for cyclosporine
metabolism during chronic treatment in the rat.
Cyclosporine is a cyclic undecapeptide of fungal origin
used for the prevention of rejection in solid organ trans-
plants and for graft-versus-host disease prophylaxis in
allogeneic bone marrow transplantation. Despite its suc-
cessful use, cyclosporine therapy is hampered by significant
dose-limiting toxicities to the kidney, liver, and central
nervous system [1, 2]. While these toxicities are related to
circulating cyclosporine concentrations, they are not always
predictable.
The major pathway for cyclosporine elimination is
through hepatic metabolism by cytochrome P450 (P450) [3,
4]. Although over 25 metabolites have been identified [5],
three predominant products are the result of either hy-
droxylation or demethylation pathways. These metabolic
pathways appear to be similar between many species,
including humans and rodents [6]. The P450 3A family is
known to be responsible for the majority of cyclosporine
metabolism [7], although other P450 enzymes have been
implicated as well [8, 9]. Modulation of hepatic P450 levels
has been shown to markedly affect cyclosporine blood
levels and toxicity [10, 11]. Induction of hepatic P450
enzymes results in a decrease in circulating cyclosporine
levels and decreased drug-associated toxicities. Conversely,
inhibition of hepatic P450 may result in cyclosporine tox-
icity.
We have recently shown that cyclosporine selectively
suppresses P450 protein expression and metabolic activity
following chronic administration in the rat [8]. The affected
P450 enzymes were were the male-specific isoforms P450
3A2 and 2C11. Following 28 days of cyclosporine adminis-
tration, male rats showed no detectable hepatic microsomal
P450 3A2 or 2C11 protein and significantly less in vitro
metabolic activity as compared with gender-matched con-
trols. Despite this, whole blood cyclosporine trough levels
were nearly half the values found in cyclosporine-treated
female rats. Thus, enzymes other than P450 3A2 are likely
to be involved with cyclosporine metabolism. Indeed, re-
cent evidence suggests that a new female-predominant
inducible P450 isoform, P450 3A9, may be involved with
drug metabolism [12].
The present study was conducted to determine whether
the suppression of P450 isoforms by cyclosporine was
dependent on the length of drug treatment, or whether the
suppression occurred close to the initiation of drug admin-
istration. We examined the time-dependent effect in our
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rat model of chronic cyclosporine nephropathy, using the
direct measurement of hepatic microsomal proteins and in
vitro microsomal enzyme activities as markers of hepatic
drug metabolism.
METHODS
Animals
Sixty male ten-week-old Sprague-Dawley rats were pur-
chased from Charles River Breeders (Wilmington, MA,
USA) and individually housed in wire-bottom cages in a 12
hours light/dark cycle animal facility with controlled humid-
ity and temperature. Following a five-day acclimation pe-
riod, rats were pair-fed a low-salt rice diet (8.5% protein,
76.6% carbohydrate, 4.3% fat, 0.05% salt, enriched with
ferric orthophosphate and thiamin mononitrate; Harlan
Teklad, Indianapolis, IN, USA) and allowed free access to
tap water [8, 13]. Prior to the initiation of the study,
approval of the protocol was given by the Institutional
Animal Use and Care Committee and all animal proce-
dures followed the Principles of Laboratory Animal Care
published by the National Institutes of Health.
Materials
Cyclosporine was provided in powder form (Sandoz
Research Institute, East Hanover, NJ, USA) and dissolved
in ethanol. The solution was diluted to 12.5% with olive oil
(12.5% vol/vol with olive oil) to a final cyclosporine con-
centration of 15 mg/ml. Furosemide was purchased from
American Reagent Laboratories, Inc. (Shirley, NY, USA).
Glucose-6-phosphate, glucose-6-phosphate dehydrogenase
(type XII), NADP (grade III), and testosterone were
purchased from Sigma Chemical Co. (St. Louis, MO,
USA). Testosterone metabolites were purchased from
Steraloids, Inc. (Wilton, NH, USA). 11a-Hydroxyprogest-
erone was purchased from Aldrich Chemical Company,
Inc. (Milwaukee, WI, USA). Acrylamide/bisacrylamide so-
lution was purchased from National Diagnostics (Atlanta,
GA, USA). Other reagents used for gel electrophoresis
were purchased from Bio-Rad Laboratories (Hercules, CA,
USA). High-performance liquid chromatography (HPLC)
grade methanol and acetonitrile were purchased from
Fisher Scientific (Pittsburgh, PA, USA). All other chemi-
cals were purchased from Sigma Chemical Co. in the
highest purity available. Goat anti-rabbit IgG, rabbit per-
oxidase anti-peroxidase, and goat anti-rabbit horseradish
peroxidase were purchased from Organon Teknika
(Durham, NC, USA).
Drug treatment
Following the acclimation period, rats were given a single
intraperitoneal dose of furosemide (4 mg/kg) to initiate salt
depletion and started on the low-salt rice diet. After one
week, weight-matched pairs of rats were administered once
daily subcutaneous doses of cyclosporine 15 mg/kg or
vehicle 1 ml/kg. One group of rats (N 5 4) was not
administered drug or vehicle and thus represented Day 0 of
the study. Additional rats were administered cyclosporine
or vehicle (N 5 4 each group) for 3, 7, 14, 21, or 28 days.
Two additional rat groups (N 5 4 each) were administered
cyclosporine 15 mg/kg 28 days and then administered
vehicle 1 ml/kg only for an additional 7 or 15 days. The final
two rat groups (N 5 4 each) were administered vehicle 1
ml/kg for a total of 35 or 43 days. Cyclosporine and vehicle
were administered at the same time each day to minimize
chronobiologic variability in drug toxicity [14]. Daily body
weights were measured. On the final day of drug or vehicle
dosing, tail blood pressures were measured (Natume
Model KN-210-1; Peninsula Laboratories, Inc., Belmont,
CA, USA). The rats were then placed into standard rodent
metabolic cages (Nalge, Rochester, NY, USA) for passive
urine collection for 24 hours. After the urine collection
period, rats were anesthetized with a single intraperitoneal
dose of ketamine 100 mg/kg. Intravenous blood samples
were collected into glass tubes containing EDTA for mea-
suring cyclosporine concentrations. An aliquot of blood was
centrifuged at 3000 3 g for 15 minutes and the plasma was
used to measure potassium. A single blood sample was
collected and allowed to clot at room temperature and the
serum was separated by centrifugation at 3000 3 g for 15
minutes and was used to measure creatinine levels. Animals
were then killed with a single lethal intravenous injection of
ketamine 200 mg/kg. The livers were removed for the
determination of hepatic microsomal activity.
Microsome isolation
Rat livers were immediately excised following sacrifice,
placed into liquid nitrogen, and stored at 270°C. Micro-
somes were isolated from livers by differential centrifuga-
tion as previously described [15]. Samples were maintained
at 4°C during the microsome preparation. In brief, aliquots
of liver tissue were homogenized in four volumes of Tris
chloride buffer, pH 7.4, containing 150 mM potassium
chloride and 1 mM EDTA, with a tissue homogenizer
(Brinkman Instruments Company, Westbury, NY, USA).
Samples were then centrifuged at 10,000 3 g for 20 minutes
at 4°C. The supernatant was collected and centrifuged at
211,000 3 g for 40 minutes at 4°C. The supernatant was
discarded and the pellet was resuspended and washed in
sodium pyrophosphate buffer, pH 7.4, containing 1 mM
EDTA with a Potter-Elvehjem tissue grinder. The suspen-
sion was centrifuged again at 211,000 3 g for 40 minutes at
4°C. The supernatant was discarded and the washed pellet
was resuspended in a tris chloride buffer, pH 7.4, contain-
ing 20% glycerol, with a ground glass tissue grinder.
Microsomes were stored at 270°C prior to analysis.
In vitro metabolism
For the determination of testosterone hydroxylation,
reaction mixtures contained 0.1 M potassium phosphate, pH
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7.4, 0.2 mg microsomal protein, 250 mM testosterone in
methanol (final concentration did not exceed 0.7% vol/vol),
and an NADPH regeneration system consisting of 0.5 mM
NADP, 10 mM glucose-6-phosphate, 10 mM magnesium
chloride, and 5 U glucose-6-phosphate dehydrogenase.
Total reaction volume was 1 ml. Mixtures were preincu-
bated at 37°C for three minutes and reactions were initiated
by the addition of glucose-6-phosphate dehydrogenase.
Incubations proceeded for 15 minutes and were quenched
by the addition of 5 ml of dichloromethane. The internal
standard (3.6 nmol of 11a-hydroxyprogesterone) was
added and the samples mixed. The organic layer was
removed and dried under reduced pressure. Dried extracts
were dissolved in 200 ml methanol and stored at 4°C until
analyzed. Samples were stable for at least four months at
4°C.
Steroid 5a-reductase activity was measured by the met-
abolic conversion of androstenedione to androstanedione
in vitro. The reaction is analogous to the testosterone
hydroxylation reaction described above except that (1)
androstenedione 250 mM was used as the substrate, (2) 60.5
nmol of internal standard (11a-hydroxyprogesterone) was
added; (3) incubation time was 20 minutes; and (4) the
samples were stable for at least two months.
Chromatography
Testosterone and metabolites were separated and quan-
tified by high pressure liquid chromatography (HPLC). In
brief, 20 ml of the extracts were injected on a Waters HPLC
system consisting of a Model U6K injector with, dual
Model 501 solvent pumps, and a Model 484 variable
wavelength detector (Millipore Corporation, Milford, MA,
USA). Metabolites were resolved at 40°C (Model CH-30
column heater; Model TC-50 controller; Eppendorf, Mad-
ison, WI, USA) on a 150 mm 3 4.6 mm C-18 column
(Supelco, Bellefonte, PA, USA) preceded by a 10 mm 3
4.3 mm C-18 guard column (Upchurch Scientific, Oak
Harbor, WA, USA). A concave gradient (curve 8) from
90% solvent A (methanol:water:acetonitrile, 39:60:1) to
85% solvent B (methanol:water:acetonitrile, 80:18:2) was
delivered over 22 minutes at 1.5 ml/min. A minimum
eight-minute washout of 90% solvent A preceded each
analysis. Absorbance was monitored at 238 nm. A Baseline
810 Chromatography Workstation (Millipore Corporation,
Milford, MA, USA) was used for gradient delivery, data
acquisition, and peak analysis. Testosterone metabolites
were quantitated by comparison of peak area ratios (me-
tabolite:internal standard) with those generated with au-
thentic standards. Rates were determined under conditions
that were linear with protein and time.
Androstenedione and reduced metabolites were sepa-
rated and quantified by HPLC using the same HPLC
system described above. Compounds were resolved at
ambient temperature on a 250 mm 3 4.6 mm C-18 column
(Microsorb MV; Rainin Instrument Co., Woburn, MA,
USA) preceded by a 10 mm 3 4.3 mm C-18 guard column
(Upchurch Scientific, Oak Harbor, WA, USA). An iso-
cratic solvent (75% methanol, 25% water) was delivered
over 12 minutes at 1 ml/min. Absorbance was monitored at
290 nm. Data were collected and analyzed in a manner
similar to that for testosterone described above.
Gel electrophoresis and immunoblot analysis
SDS-PAGE was performed by as previously described
[16] with an 8% polyacrylamide separating gel. Gibco BRL
prestained high range molecular weight markers (Life
Technologies, Gaithersburg, MD, USA) were used for
molecular weight estimation. Protein was electrophoreti-
cally transferred to nitrocellulose sheets (Schleicher and
Schuell, Keene, NH, USA) using a Genie Electrophoretic
Blotter (Idea Scientific Co., Minneapolis, MN, USA) as
previously described [17]. Rabbit anti-human P450 3A4
antibody was generously provided by Dr. Kenneth E.
Thummel (University of Washington, Seattle, WA, USA)
and rabbit anti-rat P450 2C11 antibody was generously
provided by Dr. Edward T. Morgan (Emory University,
Atlanta, GA, USA). For the detection of P450 3A4 immu-
noreactive proteins, nitrocellulose sheets were blocked with
3% NFDM in TBS and incubated with 2.5 mg/ml rabbit
anti-human P450 3A4 antibody (in 3% NFDM in TBS)
then a 1:10,000 dilution of goat anti-rabbit IgG (in 3%
NFDM in TBS), and finally a 1:10,000 dilution of rabbit
peroxidase anti-peroxidase (in 3% NFDM in TBS). For the
detection of P450 2C11 immunoreactive proteins, blocked
nitrocellulose sheets were incubated with a 1:10,000 dilu-
tion of rabbit anti-rat P450 2C11 antibody (in 3% NFDM in
TBS) then a 1:5000 dilution of goat anti-rabbit horseradish
peroxidase (in 3% NFDM in TBS). Intermediate washes
with TBS containing 0.05% Tween 20 were as previously
described [17]. Immune complexes for P450 3A4 and P450
2C11 immunoreactive proteins were detected with chemi-
luminescence using an ECL detection kit as described by
the manufacturer (Amersham, Arlington Heights, IL,
USA) using Kodak X-OMAT AR film (Eastman Kodak
Company, Rochester, NY, USA). Immunoreactive protein
band density was by direct chemiluminescence detection
(Molecular Imager; Bio-Rad).
Other assays
Urine and serum potassium concentrations were mea-
sured by flame photometry (Instrumentation Laboratories,
Lexington, MA, USA). Urine and serum creatinine, and
urine osmolality were measured by a Cobas autoanalyzer
(Roche Diagnostics, Nutley, NJ, USA). Whole blood cyclo-
sporine levels were determined by monoclonal radioimmu-
noassay (Sandoz Research Institute, East Hanover, NJ,
USA). Microsomal protein concentrations were measured
using the Folin-phenol reagent [18] with bovine serum
albumin as a standard.
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Statistical analysis
Differences between rat groups were compared using
two-factor analysis of variance. If a significant difference in
the treatment effect over time was found in the analysis of
variance model, then critical differences were determined
by multiple contrast analysis (SuperANOVA; Abacus Con-
cepts, Berkeley, CA, USA). Data are presented as mean 6
standard error. Differences were considered significant
when the probability of chance explaining the results was
reduced to less than 5% (P , 0.05).
RESULTS
All animals completed the study. The mean total body
weight of the rats at the beginning of the study was 327 6
6 g for control groups as compared with 331 6 6 g for
cyclosporine-treated groups (P . 0.05). All rats gained
weight over the study period and there was no significant
effect of drug treatment or length of treatment on weight
gain (data not shown). A summary of the effect of drug
treatment on markers of renal function is given in Figure 1.
Renal function was significantly reduced by the end of
cyclosporine dosing. This reduction was most evident be-
ginning 14 days after the start of cyclosporine dosing and
appeared to recover to baseline values 15 days after the
discontinuation of cyclosporine. Aspartate aminotransfer-
ase, a marker of drug-associated hepatotoxicity, was not
statistically different between control and cyclosporine-
treated rats during the study period (data not shown).
The regio- and stereospecific hydroxylation of testoster-
one in vitro by hepatic microsomes is an effective marker of
different P450 isoforms. A summary of the effect of cyclo-
sporine treatment on microsomal metabolism of testoster-
one is shown in Figure 2 (upper panels). Chronic cyclospor-
ine treatment significantly reduced the production of both
6b-OHT and 2a-OHT in a time-dependent manner (P ,
0.05).
In order to monitor the presence of specific P450 iso-
forms, immunoblot analysis of hepatic microsomal protein
was performed (Fig. 2, lower panels). Microsomal protein
from cyclosporine-treated rats showed a decrease in a
single immunoreactive band, consistent with P450 3A2
during drug treatment (P , 0.05). However, P450 3A2
returned to control levels 15 days after the discontinuation
of cyclosporine dosing. Similar results were found for the
detection of P450 2C11 in hepatic microsomes.
The reduction of androstenedione to androstanedione by
steroid 5a-reductase, a female-specific enzyme in the rat,
has been used to determine the degree of feminization of
male rats [8, 19]. Steroid 5a-reductase activity in cyclospor-
ine-treated rats was significantly increased during drug
treatment and returned to control levels following the
discontinuation of cyclosporine treatment (P , 0.05; Fig.
3).
Whole blood cyclosporine trough levels increased during
the first two weeks of drug treatment and remained con-
stant until the end of dosing (Fig. 4). However, after
cyclosporine dosing was stopped, the drug could be de-
tected in whole blood until the end of the study.
DISCUSSION
A clear relationship between cyclosporine dose, blood
levels, and toxicity or pharmacodynamic effects does not
Fig. 1. Markers of renal function in rats following treatment with either
cyclosporine (F) or vehicle (E) as outlined in the Methods section.
Abbreviations are: SCr, serum creatinine; CCr, creatinine clearance; FEK,
fractional excretion of potassium; UOsm, urine osmolality. Data are
expressed as mean 6 standard error of four rats in each group. *P , 0.05
as compared control rats.
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exist in transplant patients. This lack of correlation may be
due to the multitude of concurrent medications as well as
changes in the patients end organ failure over time. Even
after receiving a constant cyclosporine dosage, often blood
level monitoring demonstrates an increase in steady-state
concentrations in this patient group [20, 21]. While this
increase has been attributed to improved bioavailability
over time, the direct effect of cyclosporine on hepatic
metabolism has received little consideration. In the present
study, we investigated the effect of chronic cyclosporine
administration on hepatic cytochrome P450-mediated drug
metabolism in a rat model of chronic cyclosporine ne-
phropathy. We found that cyclosporine suppressed in vitro
hepatic microsomal activity as well as hepatic enzyme levels
in a time-dependent manner. These suppressive effects
resulted in increased blood levels of cyclosporine with
chronic administration.
In a prior study, we reported the effect of chronic
cyclosporine administration to male and female rats main-
tained on a low salt diet [8]. The study examined how 28
days of cyclosporine dosing would affect hepatic P450
protein expression and metabolic activity. At the end of the
study, male rats had no detectable hepatic microsomal
P450 3A protein. Microsomal metabolic activity was also
significantly reduced as compared with controls. Moreover,
Fig. 2. Hepatic microsomal P450 3A2 and 2C11 protein levels and
P450-dependent testosterone hydroxylation produced by rats following
treatment with either cyclosporine (F) or vehicle (E) as outlined in the
Methods section. Microsomal protein band density is indicated in arbitrary
units. 6b-OHT and 2a-OHT represent the in vitro microsomal production
of 6b-hydroxytestosterone and 2a-hydroxytestosterone, respectively. Cat-
alytic activity is expressed as nmol product/min/mg protein. Data are
expressed as mean 6 standard error of four rats in each group. *P , 0.05
as compared control rats.
Fig. 3. Steroid 5a-reductase activity in the production of androstanedi-
one by hepatic microsomes from rats following treatment with either
cyclosporine (F) or vehicle (E) as outlined in the Methods section.
Catalytic activity is expressed as nmol product/min/mg protein. Data are
expressed as mean 6 standard error of four rats in each group. *P , 0.05
as compared control rats.
Fig. 4. Whole blood cyclosporine trough levels in rats administered
cyclosporine 15 mg/kg/day by subcutaneous injection for up to 28 days
and then following drug discontinuation for an additional 15 days. Data
are expressed as mean 6 standard error of four rats in each group. *P ,
0.05 as compared with rats administered cyclosporine for three days.
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hepatic microsomal P450 2C11 protein, another male-
specific P450 isoform, was also absent. Female rats, despite
the absence of detectable P450 3A isoforms, had steady-
state cyclosporine blood levels that were approximately
one-half those of their male counterparts, indicating that
P450-dependent cyclosporine clearance was greater in the
females and that P450 enzymes other than P450 3A may be
involved with cyclosporine metabolism. This study shows a
time-dependent nature of reduction in P450 metabolism
and further supports a role for isoforms other than P450
3A2 in cyclosporine metabolism over time.
In the present study, rats administered cyclosporine
developed significant nephrotoxicity as measured by in-
creases in serum creatinine and decreases in 24 hours
creatinine clearance (Fig. 1). Within 14 days of cyclospor-
ine administration, drug-treated rats showed significant
signs of nephrotoxicity that remained until one week after
the discontinuation of drug treatment. Thus, the functional
damage caused by cyclosporine in this model appears to be
reversible after removal of the drug. However, previous
work using this model has shown that the structural damage
that occurs after four weeks of cyclosporine treatment is
not reversible [8, 13]. Further evidence of nephrotoxicity is
shown by the increases in fractional excretion of postassium
(FEK) 14 days after the start of cyclosporine dosing and the
significant decrease in urinary osmolality after one week
(Fig. 1).
Many drugs and natural products modulate hepatic drug
metabolism through their action on P450 isoforms. While
this modulation may lead to significant drug interactions,
this modulation may also be exploited for therapeutic
benefit [22–26]. In rats, cyclosporine has been shown to
alter hepatic microsomal activity as well as hepatic protein
expression [8, 27, 28]. In microsomes isolated from rats
administered cyclosporine over the study period, there was
a rapid decrease in both of the male-specific isoforms, 2C11
and 3A2 (Fig. 2). This suppression of protein expression
was sustained during the period that cyclosporine was being
given. However, two weeks after the discontinuation of
cyclosporine, P450 2C11 and 3A2 protein expression re-
turned to control levels. A similar pattern was noted when
measuring in vitro hepatic microsomal catalytic activity,
using the production of 6b-OHT and 2a-OHT as markers
of P450 3A2 and 2C11 metabolic activity, respectively [29,
30].
During the first week of cyclosporine or vehicle dosing
there is a notable drop in hepatic microsomal P450 protein
expression and catalytic activity (Fig. 2). Following this
initial drop, microsomal levels of P450 3A2 and 2C11
recover to pre-drug treatment levels in rats given vehicle
only. However, the microsomal P450 protein levels and
catalytic activites continue to decrease in rats administered
cyclosporine. The cause of this initial drop in hepatic
protein P450 levels is not clear and may be due to the initial
effects of the low salt diet or due to vehicle administration.
In either case, rats appear to recover from this depression
in activity, despite the continuation of both diet and vehicle
administration. Therefore, this reduction appears to be
separate from a cyclosporine-induced effect. While reports
in the literature have examined the effect of changes in
dietary salt or oil intake, no studies have examined the
combined effect of both agents. The effect of increased
dietary salt resulted in an increase in renal microsomal
P450 in rats [31] as well as intestinal P450 3A activity in
humans [32]. However, few data are available about the
effect of salt restriction on P450 protein expression or
metabolic activity. Dietary supplements of lipids were
shown to increase P450 content and activity in livers of rats
[33, 34]; however, the amounts of dietary lipids given were
much greater than those used in the present study. Thus, it
is not likely that either agent alone would account for the
initial suppression of hepatic microsomal P450 seen in the
present study.
The mechanism of the cyclosporine-induced suppression
of hepatic P450 remains unclear, but may be related to
alteration in endocrine function. Regulation of P450 3A2
and 2C11 in adult rats is governed by the secretion pattern
of growth hormone [35, 36]. A high-amplitude, low-fre-
quency secretion pattern is indicative of male-specific he-
patic P450 protein expression, whereas a low-amplitude,
high-frequency secretion pattern is characteristic of female-
specific protein expression. Our previous work suggested
that an alteration in this growth hormone secretion may be
responsible for the “feminization” of the male rats admin-
istered cyclosporine for 28 days [8]. Rats that were admin-
istered cyclosporine had a significant increase in the fe-
male-specific hepatic enzyme 5a-reductase. Levels of this
enzyme were significantly elevated after 14 days of cyclo-
sporine treatment and peaked at 28 days after the start of
dosing (Fig. 3). Following the discontinuation of cyclospor-
ine dosing, the activity of 5a-reductase returned to the
control level. Results from the present study are consistent
with cyclosporine altering the release pattern of growth
hormone in male rats making it similar to female rats. The
slow, progressive effect of cyclosporine treatment on he-
patic P450 protein expression and catalytic activity suggests
that the effects were not immediate on the protein, but
involves another mechanism.
The effect of chronic cyclosporine treatment on its own
steady-state blood levels is shown in Figure 4. The increase
in cyclosporine levels corresponds to the decrease in he-
patic microsomal protein expression and in vitro metabolic
activity. Furthermore, the increased cyclosporine levels
correspond to the development of renal dysfunction in
these rats. Since the half-life of cyclosporine following
single dose and acute administration in the rat is approxi-
mately eight hours [14, 37], it is apparent that during the
first two weeks of dosing, rats administered cyclosporine
are not truly at steady state. This is consistent with the
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pattern of suppression of hepatic P450 3A2 seen in the rats
in this study. It appears that after two weeks of cyclosporine
administration, the rats have established a new steady state,
which is indicative of a decrease in hepatic P450 3A2
metabolic activity. While there is not necessarily an analogy
to the regulation of P450 in humans, the present study does
provide some insight into a possible mechanism for the
progressive changes in steady-state cyclosporine levels of-
ten seen in transplant patients.
In summary, results from the present study show that
chronic cyclosporine administration in a rat model of
drug-associated nephropathy causes a significant, progres-
sive suppression of hepatic microsomal P450 isoforms
along with a corresponding decrease in microsomal cata-
lytic activity. This suppression causes an increase in cyclo-
sporine steady-state blood levels and the progression of
renal dysfunction. The cause of this change in hepatic
metabolic activity may possibly involve an alteration in
circulating growth hormone levels or other endocrine reg-
ulation of hepatic microsomal P450 in the rat. Further-
more, a role for metabolic pathways other than P450 3A2 is
suggested. Studies are ongoing to address the mechanism
and clinical relevance of these time-dependent changes in
cyclosporine metabolism.
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